These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1344 related items for PubMed ID: 16730270

  • 1. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF.
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [Abstract] [Full Text] [Related]

  • 2. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 3. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE.
    Semin Oncol; 2006 Apr 10; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [Abstract] [Full Text] [Related]

  • 4. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 5. Update of the BIG 1-98 Trial: where do we stand?
    Joerger M, Thürlimann B.
    Breast; 2009 Oct 29; 18 Suppl 3():S78-82. PubMed ID: 19914548
    [Abstract] [Full Text] [Related]

  • 6. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM.
    Expert Rev Anticancer Ther; 2007 May 29; 7(5):627-34. PubMed ID: 17492927
    [Abstract] [Full Text] [Related]

  • 7. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 29; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 8. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
    Goss PE.
    Breast Cancer Res Treat; 2008 Dec 29; 112 Suppl 1():45-52. PubMed ID: 18785006
    [Abstract] [Full Text] [Related]

  • 9. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M, Rody A.
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun 01; 126(2):146-54. PubMed ID: 16621229
    [Abstract] [Full Text] [Related]

  • 10. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE.
    Breast Cancer Res Treat; 2006 Oct 01; 99(3):295-300. PubMed ID: 16541302
    [Abstract] [Full Text] [Related]

  • 11. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R.
    Clin Cancer Res; 2005 Aug 15; 11(16):5671-7. PubMed ID: 16115902
    [Abstract] [Full Text] [Related]

  • 12. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE.
    Cancer; 2004 Sep 15; 101(6):1311-22. PubMed ID: 15368322
    [Abstract] [Full Text] [Related]

  • 13. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 15; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 14. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D, Thuerlimann B.
    Expert Rev Anticancer Ther; 2006 Jan 15; 6(1):5-10. PubMed ID: 16375638
    [Abstract] [Full Text] [Related]

  • 15. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D, Williamson D.
    Cancer Treat Rev; 2008 Apr 15; 34(2):137-44. PubMed ID: 18006236
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL.
    N Engl J Med; 2003 Nov 06; 349(19):1793-802. PubMed ID: 14551341
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE, El-Ouagari K, Karnon J, Sofrygin O.
    Breast Cancer Res Treat; 2008 Apr 06; 108(3):375-87. PubMed ID: 17653859
    [Abstract] [Full Text] [Related]

  • 18. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT, Robert NJ.
    Eur J Cancer; 2005 Aug 06; 41(12):1678-89. PubMed ID: 16098456
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
    Lancet Oncol; 2008 Jan 06; 9(1):23-8. PubMed ID: 18083065
    [Abstract] [Full Text] [Related]

  • 20. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.